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Objective: The objective of the study was to look for uncoupling protein 3 (UCP3) gene variants in early-onset severe childhood
obesity and to determine their effect on long-chain fatty acid oxidation and triglyceride storage.
Methods and results: We identified four novel mutations in the UCP3 gene (V56M, A111V, V192I and Q252X) in 200 children
with severe, early-onset obesity (body mass index-standard deviation score 42.5; onset: o4 years) living in Southern Italy. We
evaluated the role of wild-type (wt) and mutant UCP3 proteins in palmitate oxidation and in triglyceride storage in human
embryonic kidney cells (HEK293). Palmitate oxidation was B60% lower (Po0.05; Po0.01) and triglyceride storage was higher
in HEK293 cells expressing the four UCP3 mutants than in cells expressing wt UCP3. Moreover, mutants V56M and Q252X
exerted a dominant-negative effect on wt protein activity (Po0.01 and Po0.05, respectively). Telmisartan, an angiotensin II
receptor antagonist used in the management of hypertension, significantly (Po0.05) increased palmitate oxidation in HEK293
cells expressing wt and mutant proteins (Po0.05; Po0.01), including the dominant-negative mutants.
Conclusions: These data indicate that protein UCP3 affects long-chain fatty acid metabolism and can prevent cytosolic
triglyceride storage. Our results also suggest that telmisartan, which increases fatty acid oxidation in rat skeletal muscle, also
improves UCP3 wt and mutant protein activity, including the dominant-negative UCP3 mutants.
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Context: Human uncoupling protein 3 (UCP3) is the muscle-
specific mitochondrial transmembrane carrier that uncouples
oxidative adenosine-5’-triphosphate (ATP) phosphorylation.
Introduction
Human uncoupling protein 3 (UCP3) is a member of a family
of mitochondrial inner membrane anion carrier proteins
that uncouples the oxidative phosphorylation from adeno-
sine-5’-triphosphate synthesis.
1,2 The UCP3 gene consists of
seven exons, six of which encode a transmembrane region. It
encodes two forms of transcripts: a full-length messenger
(UCP3L) and a short isoform (UCP3S) that lacks the sixth
transmembrane domain; the two messengers are equally
expressed in skeletal muscle.
3 The UCP3 protein is more
abundant in glycolytic, type 2 human muscle fibers than in
oxidative, type 1 human muscle fibers. It is also expressed,
although at lower levels, in cardiac muscle and white adipose
tissue.
4,5 Several lines of evidence suggest that UCP3 is
related to cellular fatty acid metabolism rather than to
mitochondrial uncoupling of oxidative phosphorylation. In
fact, UCP3 messenger expression in skeletal muscle is rapidly
upregulated during fasting, acute exercise and high dietary
intake of fat,
6–9 and declines in situations in which fat
oxidative capacity is improved, such as after endurance
training or weight reduction, and in type 1 muscle fibers that
are characterized by a high rate of fat oxidation.
10,11 The
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www.nature.com/ijoUCP3 gene has recently been proposed as a candidate gene
for obesity.
12
In the present study, we looked for UCP3 variants in a
cohort of severe obese children (body mass index-standard
deviation score 42.5) with early-onset obesity (mean age 4
years) living in Southern Italy. We found four novel
mutations in the UCP3 gene, all in the heterozygous state.
We conducted a functional analysis of wild-type (wt) and
mutant UCP3 proteins to assess their role in long-chain fatty
acid b-oxidation and triglyceride storage.
We also investigated the association between the  55C/T
polymorphism in the UCP3 gene promoter and BMI in our
cohort, because only recent studies found an association
between the UCP3  55 C/T polymorphism and BMI in some
populations.
Telmisartan and valsartan are two angiotensin II receptor
blockers frequently used to ameliorate hypertension in
patients who are prone to visceral obesity, metabolic
syndrome and diabetes.
13 Recently, telmisartan, but not
valsartan, was found to improve long-chain fatty acid
oxidation in rat skeletal muscle
14 and to reduce lipid
accumulation in liver.
13 It also ameliorates hypertension,
improves glucose and lipid metabolism and protects against
visceral fat accumulation. In this paper, we also tested the
effects of telmisartan treatment on UCP3 wt and mutant
protein activity in HEK293 cells.
Subject and methods
Subjects
Between 2003 and 2005, 200 obese children (107 girls
(53.5%) and 93 boys (46.5%); 1.5–10 years of age) were
recruited by the outpatient clinic of the Department of
Pediatrics, ‘Federico II’ University of Naples and by the
Department of Pediatrics, A. Cardarelli Hospital, Naples,
Italy. All children were Caucasian and lived in the Campania
region (Southern Italy). Inclusion criteria were obesity
classified as BMI (weight/height
2) 495th centile, obesity
onset o10 years of age and absence of any syndromic or
endocrine form of obesity. As controls, 100 (54 males and 46
females) normal-weight healthy individuals (BMI o25kgm
–2;
aged 24.2±3.4 years), previously enrolled by us,
15 under-
went genetic testing for obesity.
Written informed consent was obtained from participants
and/or their parents. The study was approved by the ethics
committee of the School of Medicine, University of Naples
‘Federico II’ and was conducted in accordance with the
principles of the Helsinki II Declaration.
Physical measurements
A trained dietitian measured the height, weight and waist
circumference (recorded to the nearest 0.1cm, 0.1kg and
0.1cm, respectively) of the enrolled children. Waist was
measured with a flexible steel tape measure while children
were in the standing position after gentle expiration. BMI
percentiles for age and BMI-standard deviation scores were
determined based on the Center for Disease Control
normative curves.
16 Blood pressure was measured with an
aneroid sphygmomanometer on the left arm with the
subject supine after 5min of rest, with an appropriately
sized cuff.
17 Systolic (Korotkoff phase I) and diastolic blood
pressure (Korotkoff phase V) were measured three times and
the average was used for analysis.
Laboratory measurements
After a 12-h overnight fast, plasma glucose and insulin, and
serum triglycerides, total cholesterol and high-density
lipoprotein cholesterol were measured in enrolled children.
Insulin resistance was calculated with the homeostasis
model assessment of insulin resistance (HOMA-IR) index
(fasting insulin fasting glucose/22.5), as described by
Matthews et al.
18 HOMA-IR X2.5 was considered an index
of impaired insulin sensitivity. The general characteristics of
the obese children are reported in Table 1.
Body composition was evaluated with bioimpedance
analysis (STA/BIA; Akern, Florence, Italy) in children carry-
ing a UCP3 mutation and in their matched controls.
DNA amplification and genotyping
Genomic DNA was obtained from whole blood of obese and
non-obese subjects using Nucleon BACC-2 (GE Healthcare
Europe–Amersham, Little Chalfont, UK). The UCP3 gene was
amplified in a final volume of 50ml containing 50ng of
genomic DNA; 1U of Taq DNA polymerase (Invitrogen S.r.l.,
Table 1 Clinical and biochemical characteristics of the severely obese
children (n¼200) genotyped
Parameters Mean values±s.d. Normal value range
Age (years) 5.5±3.2
BMI (kgm
–2) 26.4±3.7
BMI-SDS 3±0.75 (o2)
Waist-to-hip ratio 0.97±0.06 (o0.88)
Hip circumference 79.8±9.2 (o57.1cm)
SBP 94.5±13.7 (o111mmHg)
DBP 61.5±7.1 (o71mmHg)
Triglycerides 82.5±41.8 (o103mgdl
–1)
Cholesterol 160.6±31.9 (o180mgdl
–1)
LDL cholesterol 95.9±30.0 (o130mgdl
–1)
HDL cholesterol 46.9±11.1 (4 36mgdl
–1)
AST 27.8±5.4 (10–40Ul
–1)
ALT 24.8±10.2 (o40Ul
–1)
TSH 2.7±1.2 (0.54–4.53mUml
–1)
FT3 4.4±0.5 (3.0–9.1pmoll
–1)
FT4 1.2±0.2 (0.85–1.75ngdl
–1)
HOMA 2.2±1.4 (o2.5)
Insulin 10.82±41.8 (o28mUml
–1)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransfer-
ase; BMI-SDS, body mass index-standard deviation score; DBP, diastolic blood
pressure; FT3, free triiodothyronine; FT4, free thyroxine; HDL, high-density
lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipo-
protein; SBP, systolic blood pressure; TSH, thyroid-stimulating hormone.
Values are means±s.d.; numbers in parenthesis indicate the normal range
corrected for the sample mean age (5.5±3.2 years).
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50mM KCl, 10mM Tris-HCl (pH 8.8), 2.5mM MgCl2,
0.2mgml
–1 bovine serum albumin (BSA) and 200nM of the
specific primers. The primers used for UCP3 gene sequencing
are here reported:
PCR fragments were separated by electrophoresis on a
1.5% agarose gel and purified. The two strands were
sequenced (BigDye Terminator v3.1 cycle sequencing meth-
od on an ABI-Prism 3100 Genetic Analyzer; Applied
Biosystems, Foster City, CA, USA).
Cloning of human wt and mutant UCP3 complementary
(c)DNAs in a eukaryotic expression vector
Total mRNA from a human osteosarcoma cell line (Saos-2)
expressing UCP3 protein was reverse transcribed using oligo
(dT). UCP3L and UCP3S cDNAs were amplified in PCR reactions
using the same 50-primer (CTTCCAGGACTATGGTGG) but
different 30-primers: GTTCAAAACGGTGATTCCCG for UCP3L
and GAAAGAAGCCCCTGTTCTCTG for UCP3S, respectively.
19
UCP3L and UCP3S cDNAs were inserted into the mammalian
expression vector p3xFLAG-CMV-7.1 (Sigma-Aldrich S.r.l.,
Milan, Italy) downstream from the N-terminal 3  FLAG
epitope and then sequenced in both directions. QuickChange
site-directed mutagenesis kit (Str a t a g e n eI n c . ,L aJ o l l a ,C A ,U S A )
was used to generate the four mutants (V56M, A111V, V192I
and Q252X) from the cloned wt UCP3L cDNA according to the
manufacturer’s protocol. Recombinant constructs were purified
using a Qiagen column (Qiagen S.p.A., Milan, Italy) and
sequenced on both strands.
Cell culture and UCP3 protein expression
HEK293 cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum,
100unitsml
–1 penicillin and 100mgml
–1 streptomycin
(Invitrogen S.r.l.) at 371C with 5% CO2. The plasmids
expressing the wt or the mutated UCP3 proteins were
transiently transfected in HEK293 cells using Lipofectamine
2000 reagent (Invitrogen S.r.l.) according to the manufac-
turer’s instructions. The pRL CMV vector (Promega Italia
S.r.l., Milan, Italy) expressing the Renilla luciferase cDNA
(Rluc) reporter gene was co-transfected (0.1mg) and used as
internal control reporter to verify transfection efficiency.
All the experiments were performed at 24h post-transfec-
tion: at this time, we verified that the wt and mutants UCP3
proteins were expressed in appreciable amounts and cor-
rectly localized in the mitochondria. We also performed a
cell-viability test, using Trypan blue (Sigma-Aldrich S.r.l.)
according to the manufacturer’s protocol and we observed
100% cell viability at 24h post-transfection.
Preparation of mitochondrial and submitochondrial extracts
and western blot
HEK293 cells were transiently transfected with plasmids that
express wt or mutant UCP3 proteins. At 24h after transfec-
tion, cells were washed in phosphate-buffered saline (PBS)
pH 6.9 (Sigma-Aldrich S.r.l.), harvested and mitochondrial
protein extracts were prepared using the Qproteome Mito-
chondria Isolation Kit (Qiagen S.p.A.) according to the
manufacturer’s instructions. Submitochondrial protein ex-
tracts were prepared from mitochondria freshly isolated as
described above. Briefly, mitochondria were resuspended in a
hypotonic medium (10mM KCl, 2mM HEPES, pH 7.2) and
incubated for 20min on ice to swell mitochondria and break
the outer mitochondrial membrane, thereby releasing
proteins from the intermembrane space. The swollen mito-
chondria were subsequently centrifuged at 11200r.p.m. and
the supernatant (containing the soluble intermembrane
space proteins) and the pellet (containing proteins on or
associated with the inner mitochondrial membrane and
matrix) were collected. Protein concentration was deter-
mined using the Bio-Rad protein assay kit (Bio-Rad Labora-
tories S.r.l., Segrate, Milan, Italy).
For western blot analysis, 40mg of mitochondrial and
submitochondrial protein fractions were run on a 12%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
gel and transferred to a nitrocellulose membrane (GE
Healthcare Europe–Amersham). Membranes were incubated
for 1h and 30min at room temperature with specific
antibodies and then incubated for 1h with antibody–horse-
radish peroxidase-conjugated anti-mouse Ig (1:3000 Sigma-
Aldrich). Immunoreactive bands were visualized with the
enhanced chemiluminescence reagents kit (ECL; GE Health-
care Europe–Amersham) according to the manufacturer’s
instructions. We used antitumor necrosis factor type 1
associated protein, TRAP-1 antibody (1:1000; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), anti-COX-IV
mouse monoclonal antibody (1:1000; Santa Cruz Biotech-
nology Inc.), anti-FLAG antibody (1:5000) and anti-tubulin
antibody (1:500; Sigma-Aldrich S.r.l.).
20,21
Palmitate oxidation and telmisartan treatment
Wt and mutant UCP3 proteins were expressed in HEK293
cells to evaluate the role of UCP3 in long-chain fatty acid
Promoter-Fw 50-GCGTCCACAGCTTAAAGGAG-30
Promoter-Rev 50-GAACAAGGAGAAGGGAGAGG-30
UCP3-F2 50-ATCACTCCATCAGCCTTCTC-30
UCP3-F2 50-TCTTTGTCAGGGTTCTGAGG-30
UCP3-F3 50-CAGCATGGTTGTTCTCAGGC-30
UCP3-F3 50-TGCCTCTGAGTCTAGACTTC-30
UCP3-F4 50-AGGAGGTCTGAGTGGACATC-30
UCP3-F4 50-GTCAGTGAAGTATCTTTGGTTGTG-30
UCP3-F5 50-CATTTCTCCCATTTCCCATTCC-30
UCP3-F5 50-TCCTTCTAAAACCCAGTTGCC-30
UCP3-F6 50-TTGGGGACAAACAGTGCATAC-30
UCP3-F6 50-GTACTCTTCACCGCTACATC-30
UCP3-F7 50-GAGAGCACACGCATCTGTTG-30
UCP3-F7 50-TCTGTGTCCATGTGTGCGTG-30
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transiently transfected with either wt or mutant UCP3-
expressing constructs alone or with wt and mutant UCP3-
expressing constructs in equal amounts (1:1 ratio), such that
the amount of DNA transfected each time was the same
(namely, 0.8mg). The pRL CMV vector was also co-trans-
fected. Palmitate oxidation was measured as reported else-
where.
22 Briefly, 24h after transfection, cells were washed
with PBS and incubated with 500ml of preincubation
medium (Krebs Ringer Bicarbonate Medium; Sigma-Aldrich
S.r.l.) containing 0.5gl
–1 BSA (fatty acid free; Sigma-Aldrich
S.r.l.) for 1h. After preincubation, the medium was removed
and 200ml of incubation medium (110mmoll
–1 palmitate,
16.7Ciml
–1 [
3H] palmitate and 0.5gl
–1 BSA in PBS) were
added to each well, which were incubated at 371C for 2h.
The incubation medium was transferred to columns contain-
ing B3ml of Dowex-1 ion-exchange resin (Sigma-Aldrich
S.r.l.) previously charged with 1.0moll
–1 NaOH and washed
with MilliQ water until the eluate had the same pH as the
water. Then, each well was washed once with 300ml of PBS
that was collected and applied to the columns. The columns
were finally washed with 2ml of water. The resin binds the
nonmetabolized palmitate and allows the tritiated water
produced by b-oxidation to pass through. The eluate (2.5ml)
was collected in a scintillation vial. Then, 6ml of scintilla-
tion cocktail (Picofluor 40; Packard Instruments Co Inc.,
Downers Grove, IL, USA) was added to each vial and the vials
were counted in a liquid scintillation counter Tri-CARB 1500
(Packard Instrument Co Inc.). For each sample, counts per
min (c.p.m.) were normalized to the luciferase activity
determined by the Dual-Luciferase Reporter Assay System
(Promega Italia S.r.l.), according to the manufacturer’s
instructions. The background signal was determined on
untransfected control cells.
To evaluate the effects of the angiotensin II antagonist
telmisartan on long-chain fatty acid b-oxidation in the
presence of wt and mutated UCP3 proteins, HEK293 cells
were transfected with wt UCP3L-expressing construct alone
or co-transfected with wt and mutant UCP3-expressing
constructs in equal amounts (1:1 ratio). At 24h after
transfection, cells were incubated first with 500mlo f
preincubation medium for 1h at 371C and then with
200ml of a medium containing 110mmoll
–1 palmitate and
0.5gl
–1 BSA in PBS for 3h. After the first 30min, telmisartan
(Sigma-Aldrich S.r.l.) was added to the medium at a final
concentration of 10mM,
14 and the incubation was continued
for an additional 1h and 30min. During the last 1h of
incubation, [
3H] palmitate (16.7Ciml
–1) was added to the
cells. Lastly, palmitate oxidation was measured in the
medium, as reported above.
Oil Red O staining
Intracellular triglyceride accumulation was determined by
Oil Red O staining. Briefly, HEK293 cells were seeded in poly-
D-lysine eight-well culture slides (VWR International S.r.l.,
Milan, Italy), and transiently transfected with either wt or
mutant UCP3-expressing plasmids alone or with wt and
mutant UCP3 constructs in a 1:1 ratio, such that the amount
of DNA transfected each time was the same (namely, 0.4mg).
At 24h after transfection, cells were treated with 500mM and
1m M palmitate (Sigma-Aldrich, S.r.l.) complexed with BSA for
24h. Then, cells were washed twice with PBS, fixed in a 10%
formalin-containing PBS solution for 15min and stained
with Oil Red O working solution (5mg Oil Red O ml
 1
isopropanol) for 15min at room temperature. Cells were
counterstained with hematoxylin and then covered with a
coverslip. The stained lipids were viewed and photographed
using a phase-contrast microscope (Leica Microsystems S.r.l.,
Milan, Italy) at  40 magnification. The number of Oil Red
O-stained lipid droplets/number of cells were counted. At least
five randomly chosen fields were counted for each sample.
Statistical analysis
Allele frequencies were calculated by allele counting, and the
deviation from Hardy–Weinberg equilibrium was evaluated
by w
2 analysis. The difference between metabolic and
anthropometric variables in the two groups, wt and hetero-
zygous mutation carriers, was evaluated by one-way analysis
of variance. The statistical analysis was performed with SPSS
software, version 10 (IBM, Chicago, IL, USA). The data
relative to functional analysis are shown as mean±s.d. and
were analyzed with the Student’s t-test. Differences were
considered statistically significant at a P-value of o0.05.
Results
Clinical, biochemical and genetic features of study participants
All clinical and biochemical parameters were within refer-
ence intervals for the mean age of the sample (Table 1). The
200 obese children had only high BMI-standard deviation
score (mean 3) and waist-to-hip ratio (mean 0.97) values as
expected in a sample with an average age of 5.5 years and
early-onset obesity o4 years. Clinical (BMI, diastolic and
systolic blood pressure) and biochemical characteristics
(serum total cholesterol, triglycerides, glucose, aspartate
aminotransferase and alanine aminotransferase) of the
control normal-weight young subjects were in the reference
range for the mean age of the sample (24.2 years).
15
To determine whether UCP3 gene variants contribute to
the early-onset of obesity, we genotyped the cohort of
severely obese children and 100 normal-weight non-diabetic
subjects living in Southern Italy. We found three novel
missense (V56M, A111V and V192I), one non-sense (Q252X,
which generates a truncated protein) and two silent (S101S
and A122A) mutations in the obese children and one
polymorphism (V9V) in two normal-weight and two obese
children. We also found a nucleotide change (10372 C/T) in
intron 4 in one obese child (Table 2). All mutations are in the
heterozygous state; mutations A111V, V192I and Q252X
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was found in two male siblings and in an unrelated girl
(Table 2). We also analyzed the  55C/T polymorphism in the
promoter region of the UCP3 gene in the obese and control
groups. The genotype distribution for UCP3  55C/T (CC, CT,
TT) was in Hardy–Weinberg equilibrium. Genotype and
allele frequencies did not differ between obese and non-
obese subjects (Table 2).
To exclude the involvement of other obesity gene variants
in the increased fat mass in our obese subjects, we genotyped
them for POMC, MC4R and UCP1 variants, but found no
mutations.
The parents of the 200 obese children were invited to
undergo genotyping to determine the mode of transmission
of mutations in families, but only the parents of the girl
carrying mutation V56M consented to genotyping. As
shown in Figure 1, the mother, who was severely obese
(BMI 50.6), carried mutation V56M in the heterozygous
state, similar to her daughter. Furthermore, she had waist
circumference of 114cm (normal 80cm) and was affected
by type 2 diabetes and hypertension. Mutation V56M was
absent from the father, who was overweight (BMI 29.4) and
also affected by type 2 diabetes, hypertension and dyslipi-
demia. Their daughter was severely obese (BMI 43.5); of her
two sisters, one was overweight (BMI 26.3) and the other was
obese (BMI 33.8), but they were not available for genotyping.
Interestingly, the three children carrying mutation V56M
had a much higher percentage of fat mass (B50.0%) than the
children carrying other UCP3 gene mutations (between 36
and 45%). Furthermore, the girl carrying mutation V56M
(see Figure 1) had elevated systolic blood pressure
(130mmHg), low levels of high-density lipoprotein choles-
terol (39mgdl
–1), high levels of low-density lipoprotein
cholesterol (113.4mgdl
–1) and a high HOMA index (11.3).
Hence, this girl had three components of the metabolic
syndrome, as did her parents, plus insulin-resistance.
Table 2 Mutations and polymorphisms detected in the UCP3 gene in severely obese children (n¼200) and non-obese controls (n¼100) living in Southern Italy
Region Nucleotide change Amino-acid change Obese, n (%) Control group, n (%)
UCP3 variants
50-UTR  55 C/C; C/T; T/T F 143 (75.6); 44 (23.3); 2 (1) 65 (73.6); 22 (25.3); 1 (1.1)
Exon 2 8990 G/A V9V 2 (1) 2 (2)
Exon 3 9666 G/A V56M 3 (1.5) F
Exon 3 9832 C/T A111V 1 (0.5) F
Exon 3 9576 C/T S101S 1 (0.5) F
Exon 4 10099 C/T A122A 1 (0.5) F
Exon 5 11449 G/A V192I 1 (0.5) F
Exon 6 12105 C/T Q252X 1 (0.5) F
Intron 4 10372 C/T F 1 (0.5) F
Abbreviations: UCP3, uncoupling protein 3; UTR, untranslated region.
Figure 1 Pedigree of the family with the V56M mutation. The arrow indicates the female proband carrying the V56M mutation. Status for BMI (kgm
–2), % fat mass
(% FM), type 2 diabetes mellitus (type 2 DM), blood pressure, dyslipidemia and HOMA are indicated.
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fatty acid metabolism
We investigated the effects of wt UCP3 proteins and V56M,
A111V, V192I and Q252X mutant proteins on long-chain
fatty acid oxidation and triglyceride storage in HEK293 cells.
HEK293 cells are, at present, the most widely used cell line
for in vitro studies in which expression plasmids are
transfected in order to produce proteins (also channel
proteins) and to study their activity. Wild-type long and
short UCP3 isoforms and mutant proteins were expressed in
HEK293 cells that lacked endogenous UCP3 protein in the
mitochondria. First, we evaluated the correct targeting of wt
and mutant proteins in the inner membrane and matrix
(IMM) using mitochondrial and sub-mitochondrial protein
fractions from HEK293-expressing wt or mutated UCP3
proteins. Both wt UCP3L and UCP3S isoforms were correctly
localized in the IMM, and were absent in the intermembrane
space (Figure 2a, lanes 2–4 and 17–19, respectively).
Similarly, all UCP3 mutant proteins were correctly localized
in IMM, and were absent in the intermembrane space
(Figure 2a, lanes 7, 10, 13, 16 and lanes 6, 9, 12, 15,
respectively).
We next evaluated the b-oxidation capacity of palmitate, a
long-chain fatty acid, in HEK293 cells expressing wt or
mutant UCP3 proteins and treated with
3H-labeled palmi-
tate. Palmitate b-oxidation capacity was evaluated by
measuring tritiated water produced by cells and it was
expressed as a percentage of UCP3L activity, taken as 100%.
The UCP3S isoform retained 55% of UCP3L activity
(Figure 2b); moreover, palmitate oxidation was significantly
reduced in HEK293 cells expressing the mutated proteins. In
particular, V56M and Q252X mutants retained only 40 and
35% of UCP3L activity, respectively. A111V and V192I
retained B45% of UCP3L activity (Figure 2b).
Because all mutations were found in the heterozygous
state, we tested the possibility that mutated proteins can
Figure 2 Sublocalization (a) and activity (b) of wt and mutant UCP3 proteins. (a) Western blot of mitochondrial (MIT) and submitochondrial (intermembrane
space (IMS) and IMM) protein extracts (40mg) obtained from untransfected HEK293 cells (lane 1, Ctrl) and from HEK293 cells expressing wt UCP3L (lanes 2–4) and
V56M (lanes 5–7), A111V (lanes 8–10), V192I (lanes 11–13) and Q252X (lanes 14–16) mutant proteins. Protein extracts from cells expressing wt UCP3S (lanes
17–19) are also shown. A specific anti-FLAG monoclonal antibody was used to reveal wt and mutant UCP3 proteins. Anti-Trap-1 and anti-COX-IV antibodies were
used as control for IMM localization. (b) Activity of wt and mutant UCP3 proteins calculated as percentage of
3H-labeled palmitate oxidation. Percentage of
palmitate oxidation capacity of wt UCP3 isoforms (UCP3L, white bar and UCP3S, light gray bar) and of V56M, A111V, V192I and Q252X mutant proteins (black
bars) in HEK293 cells. We assigned an arbitrary value of 100% to UCP3L isoform activity. Palmitate b-oxidation capacity was also assayed in HEK293 cells
coexpressing UCP3L isoform and mutant proteins in equal amounts (V56M/UCP3L, A111V/UCP3L, V192I/UCP3L, Q252X/UCP3L and UCP3S/UCP3L, gray bars).
Data represent the means±s.d. of four different experiments. *Po0.05 and **Po0.01 represent statistical differences vs UCP3L.
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choose to refer all successive analyses to long isoform of
UCP3 (UCP3L) activity in that the UCP3L protein is the only
isoform detectable in the human skeletal muscle also using
such large amounts of protein mitochondrial extracts as
15mg.
5 To this aim, we co-transfected equal amounts of
UCP3L-expressing construct with constructs expressing
V56M, A111V, V192I or Q252X in HEK293 cells, and
evaluated the dominant-negative effect of mutated proteins
on UCP3L activity by determining palmitate b-oxidation
capacity. V56M and Q252X mutants exerted a dominant-
negative effect on UCP3L activity, whereas A111V and V192I
activity were rescued by UCP3L co-transfection (Figure 2b).
Also, the UCP3S isoform activity was only partially rescued
in co-transfected cells mimicking a slight dominant-negative
effect on UCP3L activity (Figure 2b).
Interestingly, the V56M mutant protein was associated
with higher BMI, percentage of fat mass and HOMA and
insulin values in obese children carrying UCP3 mutations.
To evaluate the role of long and short wt UCP3 isoforms in
the prevention of triglyceride storage, we treated HEK293
cells expressing wt UCP3 isoforms (long and short) or
mutant proteins with 500mM or 1mM palmitate and
evaluated triglyceride storage by Oil Red O staining. Similar
results were obtained with either palmitate concentration.
The number of Oil Red O-positive spots was significantly
lower in cells expressing the UCP3L isoform than in
untransfected cells (Control (Ctrl); Figures 3a and b, compare
UCP3L with Ctrl). As expected, neither the UCP3S isoform
nor the four mutant proteins prevented triglyceride storage
(Figures 3a and b), although at different extent, as shown by
the higher number of Oil Red O-positive spots compared
with UCP3L-expressing cells. Again, as expected, UCP3L co-
transfection partially rescued the activity of the A111V and
V192I mutant proteins as well as UCP3S isoform but did not
affect the activity of the V56M and Q252X dominant-
negative mutant proteins (Figure 3b). Interestingly, subjects
carrying V56M or Q252X dominant-negative mutations had
the highest plasma non-esterified fatty acid values, mild liver
steatosis and higher fat mass and lower free fat mass values
(data not shown).
Telmisartan improved palmitate oxidation capacity in HEK293
cells coexpressing UCP3L and mutant proteins
Telmisartan, 10mM, increases fatty acid oxidation in skeletal
muscle by activating the peroxisome proliferator-activated
receptor-g pathway.
14 Therefore, we evaluated whether
telmisartan improves palmitate b-oxidation capacity in cells
coexpressing the UCP3L isoform and mutated UCP3 pro-
teins. HEK293 cells were transiently transfected with UCP3L-
expressing construct alone or co-transfected with constructs
expressing the UCP3L and V56M, A111V, A192I and Q252X
mutant proteins in equal amounts in order to mimic the
heterozygous state of probands. Telmisartan, 10mM, was
added to the culture for 3h and long-chain fatty acid
b-oxidation capacity was evaluated in the presence of
tritiated palmitate. Palmitate oxidation capacity was calcu-
lated as percentage with respect to UCP3L-expressing cells in
the absence of telmisartan taken as 100% (Figure 4, UCP3L).
We found that 10mM telmisartan increased b-oxidation
capacity in cells expressing UCP3L, by B40% with respect
to untreated cells. b-Oxidation capacity was also significantly
higher in telmisartan-treated cells coexpressing UCP3L and
all mutant proteins than in the untreated counterpart cells
(Figure 4, compare gray with black bars). Interestingly,
telmisartan increased b-oxidation capacity by approximately
two- to three-fold in cells coexpressing UCP3L and the
dominant-negative mutants Q252X and V56M.
Discussion
Different functional roles have been postulated for UCP3:
UCP3 has been implicated in fatty acid metabolism in
conditions of excess mitochondrial fatty acid supply;
23,24
UCP3 is involved in body energy balance. In fact, mice
overexpressing human UCP3 have a lower body weight than
wt mice.
25–28 Furthermore, observational studies in humans
showed that UCP3 protein expression was reduced by 40%
after weight loss in type 2 diabetic patients,
11 and UCP3
protein expression was negatively correlated with BMI in
non-diabetic obese subjects.
29
In humans, UCP3 expression is restricted to skeletal
muscle. Because skeletal muscle is responsible for most of
the daily energy expenditure, and a reduction in energy
expenditure is a risk factor for the development of obesity,
30
UCP3 has been indicated as an obese susceptibility gene.
Furthermore, the UCP3 gene was mapped on chromosome
11q13, in a region that has been linked to obesity and
hyperinsulinemia.
31
Several UCP3 gene variants have been implicated in
obesity in humans.
32–34 The most extensively studied UCP3
variant is the  55C/T polymorphism in the promoter region.
The association of this polymorphism with overweight is
controversial. In fact, it was associated with elevated UCP3
mRNA expression in male non-diabetic Pima Indians,
35 with
an increased BMI in a French population,
36 with an
increased hip-to-waist ratio in women of Asian origin
37 and
with BMI and diabetes mellitus in a German population.
38
Conversely, the  55C/T polymorphism was associated with a
lower BMI in a UK population
39 and in US Caucasian and
Spanish populations,
40,41 whereas no association was found
between  55C/T and BMI or percentage of body fat in
Danish obese and control subjects.
42,43 In our cohort, we
found no association between  55C/T and BMI, which is in
agreement with Dalgaard and Berentzen.
42,43
Only few studies have been reported so far on the positive
association between UCP3 mutations and obese phenotype,
but no functional analyses were performed in eukaryotic
cells.
32–34 Hence, the functional analysis of the wt and
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children is the first attempt made in eukaryotic cells
to unravel the role of UCP3 in handling long-chain
fatty acids.
In our experimental system, the UCP3 short isoform is
localized in the IMM and shows a slight dominant-negative
effect on UCP3 long isoform activity. Further experiments
are required to validate the functional activity of the short
isoform of UCP3, also in muscle cells. Similarly, it will be
necessary to define in vivo the expression and the localiza-
tion of the Q252X mutant protein, which lacks the sixth
transmembrane domain.
Figure 3 Triglyceride storage of wt and mutant UCP3 proteins. (a) Oil Red O staining of HEK293 cells expressing wt UCP3L and UCP3S isoforms and mutant
V56M, A111V, V192I and Q252X UCP3 proteins treated with 1mM palmitate. Red points indicate triglyceride depots;  40 magnification. Ctrl indicates HEK293
cells not expressing UCP3 protein. (b) The number of Oil Red O-positive spots/number of cells is reported. Control (heavy gray bar) represents number of Oil Red
O-spots/number of cells in HEK293 not expressing UCP3 protein. Black bars represent Oil Red O-spots/number of cells in HEK293 expressing wt UCP3L or UCP3S
isoforms or V56M, A111V, V192I and Q252X mutant proteins; light gray bars represent Oil Red O-spots/number of cells in HEK293 coexpressing UCP3L isoform and
UCP3S isoform or mutant proteins in equal amounts (UCP3S/UCP3L, V56M/UCP3L, A111V/UCP3L, V192I/UCP3L and Q252X/UCP3L). Data represent the
means±s.d. of five different fields.
#Po0.001 vs Control; *Po0.05, **Po0.01, ***Po0.005, ****Po0.001 vs UCP3L-expressing cells.
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available, and hence we are not able to correlate the
mutations identified with the UCP3 protein structure.
Regarding the structure, we can only speculate on the type
of amino acid substitution and/or on UCP3 domains in
which the changed amino acids are located. All the data
reported in our paper regarding the domains and the
transmembrane structures of the UCP3 protein were ob-
tained from the UniProT database. V56M is a mutation that
consists of a substitution of a non-polar amino acid in an
amino acid that is also non-polar. V56 amino acid, highly
conserved in eukaryotes, falls in a domain (Ith solute
carrier¼solcar repeat) involved in transporting fatty acid
anions from the mitochondrial matrix into the intermem-
brane space. V192I is a substitution of a non-polar amino
acid in a hydrophobic amino acid. V192 amino acid, highly
conserved in eukaryotes, falls in the fourth transmembrane
domain included in the II solcar repeat. Despite the fact that
these two variants are located in important regions involved
in the transport of anions of fatty acids, they affect
differently the activity of UCP3L.
Similarly, we do not know if the Q252X variant is
essentially the same as making cells homozygous for UCP3S.
What we know is that in our experimental system, both the
Q252X mutant and the UCP3 short isoform are localized in
the mitochondria associated with the inner membrane
(IMM), but they show a different effect on UCP3L isoform
activity. In particular, the UCP3S isoform retained 55% of
UCP3L activity, whereas the Q252X mutant retained only
35% of UCP3L activity. However, as we mentioned pre-
viously,
in vivo, we never detected the UCP3S isoform in mitochon-
drial extracts from skeletal muscle biopsies. Moreover, we
have no data in vivo regarding the expression of the Q252X
mutated protein because muscle biopsies of the subject
carrying the Q252X mutation are not available.
UCP3 expression increases glucose metabolism and pro-
tects against hyperglycemia.
25,44 Moreover, UCP3 messenger
and protein expression was found to be decreased in muscle
tissue of pre-diabetic and diabetic subjects.
45,13 Because of
the early onset of obesity in our cohort (mean age 4 years),
we found no correlation between the HOMA index and the
activity of mutated UCP3 protein. However, the HOMA
index was elevated in two subjects carrying mutation V56M
(11.24 and 3.05, respectively, compared with the mean value
of 2.2 in our obese cohort), as were insulin plasma
concentrations (53.9 and 14.7, respectively, vs 10.82). We
re-examined the female proband carrying mutation V56M
10 years after the first observation when she was 17 years old.
She was still obese (BMI 47.6) and reported diet-resistant
weight gain. These data suggest a link between V56M and
severe human obesity, and extend our knowledge about the
role of UCP3 in fatty acid oxidation and in the prevention of
triglyceride storage. Interestingly, the highest percentage of
fat mass was found among obese subjects carrying the V56M
and Q252X dominant- negative mutants.
Telmisartan is both a selective peroxisome proliferator-
activated receptor modulator and an angiotensin II receptor
blocker.
13,14,46–49 Recently, it was found to be effective in the
treatment of hypertension, to improve glucose and lipid
metabolism and to protect against diet-induced weight gain
and visceral fat accumulation. Telmisartan also increased
fatty acid metabolism in murine muscle myotubes by
decreasing acetyl CoA carboxylase 2 expression, thereby
resulting in inhibition of fatty acid synthesis and stimulation
of fatty acid oxidation.
49 Finally, studies conducted in
Figure 4 Effects of telmisartan treatment on palmitate oxidation activity of wt and mutant UCP3 proteins. Oxidation of
3H-labeled palmitate in HEK293 cells
expressing either UCP3L isoform or UCP3L and mutant UCP3 proteins in equal amounts (V56M/UCP3L, A111V/UCP3L, V192I/UCP3L and Q252X/UCP3L), in the
absence (black bars) or presence (gray bars; þT) of telmisartan treatment. Data represent the means±s.d. of four different experiments reported as a percentage of
the value obtained for UCP3L-expressing cells in the absence of telmisartan treatment (UCP3L black bar) to which we assigned an arbitrary value of 100%. *Po0.05
and **Po0.005 vs UCP3L;
#Po0.05,
##Po0.005 and
###Po0.001 vs corresponding black bar (–T).
Effects of UCP3 variants on fatty acid metabolism
CV Musa et al
215
International Journal of Obesityhumans showed that telmisartan positively affected HbA1c,
total and low-density lipoprotein cholesterol and hyperten-
sion in type 2 diabetes patients.
50–52 Consequently, telmi-
sartan could be used to treat obese, type 2 diabetes with
hypertension and hence reduce the risk of cardiovascular
diseases.
In conclusion, our data support the notion that protein
UCP3 is involved in long-chain fatty acid metabolism in
mitochondria and in the prevention of cytosolic triglyceride
storage. We also provide evidence that telmisartan improves
palmitate oxidation in cells expressing the dominant-
negative UCP3 mutant proteins V56M and Q252X. Further
experiments are needed in order to test if telmisartan may be
useful in subjects in whom fatty acid metabolism is severely
impaired.
Our future aim is also to enlarge our cohort study and to
investigate if the activity of mutant-negative UCP3 proteins
is correlated with dietary fat intake and/or with the degree of
daily physical activity.
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